ErythroCure

ErythroCure is a private biotechnology company developing therapeutics for congenital and acquired blood disorders, blood-borne pathogens, and blood cell cancers. The company's science is built on insights into red and white blood cell physiology, with an initial focus on sickle cell disease and malaria. Its lead clinical validation appears to come from host-directed anti-malarial development using imatinib in combination with standard artemisinin-based therapy, which the company has described as having generated Phase 2 clinical data in Vietnam. In sickle cell disease, ErythroCure is pursuing small-molecule approaches intended to stabilize the sickle erythrocyte membrane and reduce downstream vaso-occlusive pathology. The company was co-founded by researchers including Philip Low and Francesco Turrini and is headquartered in West Lafayette, Indiana.